Improvement of [beta]-cell function after achievement of optimal glycaemic control via long-term continuous subcutaneous insulin infusion therapy in non-newly diagnosed type 2 diabetic patients with suboptimal glycaemic control

Improvement of [beta]-cell function after achievement of optimal glycaemic control via long-term continuous subcutaneous insulin infusion therapy in non-newly diagnosed type 2 diabetic patients with suboptimal glycaemic control

Background Achieving euglycaemia by continuous subcutaneous insulin infusion (CSII) therapy alone has been shown to restore [beta]-cell function in patients with newly diagnosed type 2 diabetes. However, the efficacy has not been evaluated in patients with non-newly diagnosed type 2 diabetes and sub...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes/metabolism research and reviews 2013-09, Vol.29 (6), p.473
Hauptverfasser: Choi, Soo-Bong, Lee, Jun-Ho, Lee, Ju-Han, Kim, Seonguk, Han, Sang-Don, Kim, Ick-Hee, Noh, Yun-Hee
Format: Artikel
Sprache:eng
Schlagworte:
Diabetes
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 6
container_start_page 473
container_title Diabetes/metabolism research and reviews
container_volume 29
creator Choi, Soo-Bong
Lee, Jun-Ho
Lee, Ju-Han
Kim, Seonguk
Han, Sang-Don
Kim, Ick-Hee
Noh, Yun-Hee
description Background Achieving euglycaemia by continuous subcutaneous insulin infusion (CSII) therapy alone has been shown to restore [beta]-cell function in patients with newly diagnosed type 2 diabetes. However, the efficacy has not been evaluated in patients with non-newly diagnosed type 2 diabetes and suboptimal glycaemic control. Methods Of the 1220 patients with type 2 diabetes who began CSII therapy from March 2000 to March 2007, we retrospectively selected patients using the following inclusion criteria: glycosylated haemoglobin (HbA1c)≥7.0%, diabetes duration≥1year before CSII therapy, and duration of CSII therapy≥6months. We evaluated sequential changes in HbA1c and serum C-peptide levels measured at a 6- to 12-month intervals during CSII therapy. Results In the 521 subjects included in this study [median diabetes duration 10years; interquartile range (IQR) 6.0-17.0; CSII therapy ≤30months], median HbA1c decreased from 8.7% (IQR 7.7-10.0) at baseline to 6.3% (IQR 5.9-6.9) after 6months of CSII therapy (p
doi_str_mv 10.1002/dmrr.2416
format Article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_1430360962</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3063884181</sourcerecordid><originalsourceid>FETCH-LOGICAL-p113t-276353aaf9b21ae96e1aad7a828a9c4ccfda54990ae342b5312b0ec04f9ab713</originalsourceid><addsrcrecordid>eNp1UMtOwzAQtBBIlMKBP7DEOeBHkjZHVPGoVIlLbwhVG2fTunLsENut8r38CAkgOHGa3dHszGgJuebsljMm7qqm625FyvMTMuGZYMksy9np75yJc3Lh_Z4xJtM8nZCPZdN27oAN2kBdTV9LDPCWKDSG1tGqoJ2lUAfsKKidxj-la4NuwNCt6RVgoxVVzobOGXrQQI2z22S4ar5YbaOLnvpYqhjA4rho66PRdsA6-jEl7LCDth8Iap1NLB5NTysNW-s8VjT0LVIxEkPFIa2FoIcqnh512I3W_xa6JGc1GI9XPzgl68eH9eI5Wb08LRf3q6TlXIZEzHKZSYC6KAUHLHLkANUM5mIOhUqVqivI0qJggDIVZSa5KBkqltYFlDMup-Tm23Z46HtEHzZ7Fzs7JG54KpnMWZEL-QmqYInE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1430360962</pqid></control><display><type>article</type><title>Improvement of [beta]-cell function after achievement of optimal glycaemic control via long-term continuous subcutaneous insulin infusion therapy in non-newly diagnosed type 2 diabetic patients with suboptimal glycaemic control</title><source>Wiley Journals</source><creator>Choi, Soo-Bong ; Lee, Jun-Ho ; Lee, Ju-Han ; Kim, Seonguk ; Han, Sang-Don ; Kim, Ick-Hee ; Noh, Yun-Hee</creator><creatorcontrib>Choi, Soo-Bong ; Lee, Jun-Ho ; Lee, Ju-Han ; Kim, Seonguk ; Han, Sang-Don ; Kim, Ick-Hee ; Noh, Yun-Hee</creatorcontrib><description>Background Achieving euglycaemia by continuous subcutaneous insulin infusion (CSII) therapy alone has been shown to restore [beta]-cell function in patients with newly diagnosed type 2 diabetes. However, the efficacy has not been evaluated in patients with non-newly diagnosed type 2 diabetes and suboptimal glycaemic control. Methods Of the 1220 patients with type 2 diabetes who began CSII therapy from March 2000 to March 2007, we retrospectively selected patients using the following inclusion criteria: glycosylated haemoglobin (HbA1c)≥7.0%, diabetes duration≥1year before CSII therapy, and duration of CSII therapy≥6months. We evaluated sequential changes in HbA1c and serum C-peptide levels measured at a 6- to 12-month intervals during CSII therapy. Results In the 521 subjects included in this study [median diabetes duration 10years; interquartile range (IQR) 6.0-17.0; CSII therapy ≤30months], median HbA1c decreased from 8.7% (IQR 7.7-10.0) at baseline to 6.3% (IQR 5.9-6.9) after 6months of CSII therapy (p&lt;0.0001). During the subsequent 24months, median HbA1c levels were maintained between 6.3% and 6.5% (p&lt;0.0001 for all time points vs baseline). At 12months after CSII therapy, median C-peptide levels began to increase compared with baseline (fasting level 23% increase, p&lt;0.0001; 2-h postprandial level 26% increase, p=0.022), and the increase was maintained at 30months (fasting level 39%; 2-h postprandial level 53%; p&lt;0.0001 for all vs baseline). Conclusions [beta]-Cell function was significantly improved in patients with non-newly diagnosed and suboptimally controlled type 2 diabetes after achieving and maintaining optimal glycaemic control with long-term CSII therapy alone. Copyright © 2013 John Wiley &amp; Sons, Ltd. [PUBLICATION ABSTRACT]</description><identifier>ISSN: 1520-7552</identifier><identifier>EISSN: 1520-7560</identifier><identifier>DOI: 10.1002/dmrr.2416</identifier><identifier>CODEN: DMRRFM</identifier><language>eng</language><publisher>Bognor Regis: Wiley Subscription Services, Inc</publisher><subject>Diabetes</subject><ispartof>Diabetes/metabolism research and reviews, 2013-09, Vol.29 (6), p.473</ispartof><rights>Copyright © 2013 John Wiley &amp; Sons, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Choi, Soo-Bong</creatorcontrib><creatorcontrib>Lee, Jun-Ho</creatorcontrib><creatorcontrib>Lee, Ju-Han</creatorcontrib><creatorcontrib>Kim, Seonguk</creatorcontrib><creatorcontrib>Han, Sang-Don</creatorcontrib><creatorcontrib>Kim, Ick-Hee</creatorcontrib><creatorcontrib>Noh, Yun-Hee</creatorcontrib><title>Improvement of [beta]-cell function after achievement of optimal glycaemic control via long-term continuous subcutaneous insulin infusion therapy in non-newly diagnosed type 2 diabetic patients with suboptimal glycaemic control</title><title>Diabetes/metabolism research and reviews</title><description>Background Achieving euglycaemia by continuous subcutaneous insulin infusion (CSII) therapy alone has been shown to restore [beta]-cell function in patients with newly diagnosed type 2 diabetes. However, the efficacy has not been evaluated in patients with non-newly diagnosed type 2 diabetes and suboptimal glycaemic control. Methods Of the 1220 patients with type 2 diabetes who began CSII therapy from March 2000 to March 2007, we retrospectively selected patients using the following inclusion criteria: glycosylated haemoglobin (HbA1c)≥7.0%, diabetes duration≥1year before CSII therapy, and duration of CSII therapy≥6months. We evaluated sequential changes in HbA1c and serum C-peptide levels measured at a 6- to 12-month intervals during CSII therapy. Results In the 521 subjects included in this study [median diabetes duration 10years; interquartile range (IQR) 6.0-17.0; CSII therapy ≤30months], median HbA1c decreased from 8.7% (IQR 7.7-10.0) at baseline to 6.3% (IQR 5.9-6.9) after 6months of CSII therapy (p&lt;0.0001). During the subsequent 24months, median HbA1c levels were maintained between 6.3% and 6.5% (p&lt;0.0001 for all time points vs baseline). At 12months after CSII therapy, median C-peptide levels began to increase compared with baseline (fasting level 23% increase, p&lt;0.0001; 2-h postprandial level 26% increase, p=0.022), and the increase was maintained at 30months (fasting level 39%; 2-h postprandial level 53%; p&lt;0.0001 for all vs baseline). Conclusions [beta]-Cell function was significantly improved in patients with non-newly diagnosed and suboptimally controlled type 2 diabetes after achieving and maintaining optimal glycaemic control with long-term CSII therapy alone. Copyright © 2013 John Wiley &amp; Sons, Ltd. [PUBLICATION ABSTRACT]</description><subject>Diabetes</subject><issn>1520-7552</issn><issn>1520-7560</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNp1UMtOwzAQtBBIlMKBP7DEOeBHkjZHVPGoVIlLbwhVG2fTunLsENut8r38CAkgOHGa3dHszGgJuebsljMm7qqm625FyvMTMuGZYMksy9np75yJc3Lh_Z4xJtM8nZCPZdN27oAN2kBdTV9LDPCWKDSG1tGqoJ2lUAfsKKidxj-la4NuwNCt6RVgoxVVzobOGXrQQI2z22S4ar5YbaOLnvpYqhjA4rho66PRdsA6-jEl7LCDth8Iap1NLB5NTysNW-s8VjT0LVIxEkPFIa2FoIcqnh512I3W_xa6JGc1GI9XPzgl68eH9eI5Wb08LRf3q6TlXIZEzHKZSYC6KAUHLHLkANUM5mIOhUqVqivI0qJggDIVZSa5KBkqltYFlDMup-Tm23Z46HtEHzZ7Fzs7JG54KpnMWZEL-QmqYInE</recordid><startdate>20130901</startdate><enddate>20130901</enddate><creator>Choi, Soo-Bong</creator><creator>Lee, Jun-Ho</creator><creator>Lee, Ju-Han</creator><creator>Kim, Seonguk</creator><creator>Han, Sang-Don</creator><creator>Kim, Ick-Hee</creator><creator>Noh, Yun-Hee</creator><general>Wiley Subscription Services, Inc</general><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>K9.</scope></search><sort><creationdate>20130901</creationdate><title>Improvement of [beta]-cell function after achievement of optimal glycaemic control via long-term continuous subcutaneous insulin infusion therapy in non-newly diagnosed type 2 diabetic patients with suboptimal glycaemic control</title><author>Choi, Soo-Bong ; Lee, Jun-Ho ; Lee, Ju-Han ; Kim, Seonguk ; Han, Sang-Don ; Kim, Ick-Hee ; Noh, Yun-Hee</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p113t-276353aaf9b21ae96e1aad7a828a9c4ccfda54990ae342b5312b0ec04f9ab713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Diabetes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Choi, Soo-Bong</creatorcontrib><creatorcontrib>Lee, Jun-Ho</creatorcontrib><creatorcontrib>Lee, Ju-Han</creatorcontrib><creatorcontrib>Kim, Seonguk</creatorcontrib><creatorcontrib>Han, Sang-Don</creatorcontrib><creatorcontrib>Kim, Ick-Hee</creatorcontrib><creatorcontrib>Noh, Yun-Hee</creatorcontrib><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><jtitle>Diabetes/metabolism research and reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Choi, Soo-Bong</au><au>Lee, Jun-Ho</au><au>Lee, Ju-Han</au><au>Kim, Seonguk</au><au>Han, Sang-Don</au><au>Kim, Ick-Hee</au><au>Noh, Yun-Hee</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Improvement of [beta]-cell function after achievement of optimal glycaemic control via long-term continuous subcutaneous insulin infusion therapy in non-newly diagnosed type 2 diabetic patients with suboptimal glycaemic control</atitle><jtitle>Diabetes/metabolism research and reviews</jtitle><date>2013-09-01</date><risdate>2013</risdate><volume>29</volume><issue>6</issue><spage>473</spage><pages>473-</pages><issn>1520-7552</issn><eissn>1520-7560</eissn><coden>DMRRFM</coden><abstract>Background Achieving euglycaemia by continuous subcutaneous insulin infusion (CSII) therapy alone has been shown to restore [beta]-cell function in patients with newly diagnosed type 2 diabetes. However, the efficacy has not been evaluated in patients with non-newly diagnosed type 2 diabetes and suboptimal glycaemic control. Methods Of the 1220 patients with type 2 diabetes who began CSII therapy from March 2000 to March 2007, we retrospectively selected patients using the following inclusion criteria: glycosylated haemoglobin (HbA1c)≥7.0%, diabetes duration≥1year before CSII therapy, and duration of CSII therapy≥6months. We evaluated sequential changes in HbA1c and serum C-peptide levels measured at a 6- to 12-month intervals during CSII therapy. Results In the 521 subjects included in this study [median diabetes duration 10years; interquartile range (IQR) 6.0-17.0; CSII therapy ≤30months], median HbA1c decreased from 8.7% (IQR 7.7-10.0) at baseline to 6.3% (IQR 5.9-6.9) after 6months of CSII therapy (p&lt;0.0001). During the subsequent 24months, median HbA1c levels were maintained between 6.3% and 6.5% (p&lt;0.0001 for all time points vs baseline). At 12months after CSII therapy, median C-peptide levels began to increase compared with baseline (fasting level 23% increase, p&lt;0.0001; 2-h postprandial level 26% increase, p=0.022), and the increase was maintained at 30months (fasting level 39%; 2-h postprandial level 53%; p&lt;0.0001 for all vs baseline). Conclusions [beta]-Cell function was significantly improved in patients with non-newly diagnosed and suboptimally controlled type 2 diabetes after achieving and maintaining optimal glycaemic control with long-term CSII therapy alone. Copyright © 2013 John Wiley &amp; Sons, Ltd. [PUBLICATION ABSTRACT]</abstract><cop>Bognor Regis</cop><pub>Wiley Subscription Services, Inc</pub><doi>10.1002/dmrr.2416</doi></addata></record>
fulltext fulltext
identifier ISSN: 1520-7552
ispartof Diabetes/metabolism research and reviews, 2013-09, Vol.29 (6), p.473
issn 1520-7552
1520-7560
language eng
recordid cdi_proquest_journals_1430360962
source Wiley Journals
subjects Diabetes
title Improvement of [beta]-cell function after achievement of optimal glycaemic control via long-term continuous subcutaneous insulin infusion therapy in non-newly diagnosed type 2 diabetic patients with suboptimal glycaemic control
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T11%3A48%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Improvement%20of%20%5Bbeta%5D-cell%20function%20after%20achievement%20of%20optimal%20glycaemic%20control%20via%20long-term%20continuous%20subcutaneous%20insulin%20infusion%20therapy%20in%20non-newly%20diagnosed%20type%202%20diabetic%20patients%20with%20suboptimal%20glycaemic%20control&rft.jtitle=Diabetes/metabolism%20research%20and%20reviews&rft.au=Choi,%20Soo-Bong&rft.date=2013-09-01&rft.volume=29&rft.issue=6&rft.spage=473&rft.pages=473-&rft.issn=1520-7552&rft.eissn=1520-7560&rft.coden=DMRRFM&rft_id=info:doi/10.1002/dmrr.2416&rft_dat=%3Cproquest%3E3063884181%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1430360962&rft_id=info:pmid/&rfr_iscdi=true